LCL支架OmpA环3构建体作为抗鲍曼不动杆菌疫苗候选
本研究针对多重耐药鲍曼不动杆菌,采用免疫信息学与实验验证相结合的策略,将OmpA胞外环3移植到无环C端叶(LCL)支架上设计四组杂合构建体。计算分析显示OmpAL3-P2结构最稳定、表位保留最佳;小鼠实验证实该构建体诱导Th1偏向的体液与细胞免疫,在脓毒症模型中提供显著保护并降低器官菌负荷,被动免疫确认抗体贡献。
要点
- LCL支架移植OmpA环3可保留天然构象并增强表位呈递。
- OmpAL3-P2在计算筛选中结构稳定性与表位保留最优。
- OmpAL3免疫诱导IgG2c为主、IFN-γ升高的Th1偏向应答。
核心结论
- LCL支架化的OmpA环3是抗多重耐药鲍曼不动杆菌的有前景亚单位疫苗候选。
- 基于支架的结构疫苗学可用于理性疫苗开发。
研究设计与样本
- 采用免疫信息学与实验验证整合流程,设计四组靶向OmpA胞外环3的杂合构建体。
- 计算分析包括抗原性预测、结构建模、分子动力学模拟、TLR对接与MHC-II结合评估。
- 实验验证重组表达纯化后免疫C57BL/6小鼠,并进行脓毒症攻击与被动免疫实验。
主要发现
- OmpAL3-P2表现出最优的结构稳定性、表面可及性与表位保留特征。
- OmpAL3免疫诱导强抗原特异性体液与细胞免疫,IgG升高、IgG2c为主、脾细胞增殖增强、IFN-γ分泌增加。
- 小鼠脓毒症攻击模型中OmpAL3提供显著保护、降低主要器官细菌负荷并保持组织完整性。
- 被动免疫实验证实疫苗诱导抗体对保护作用的贡献。
临床怎么用
- 为多重耐药鲍曼不动杆菌疫苗开发提供候选构建体与结构疫苗学设计思路。
- 提示需进一步开展临床前安全性与保护力评估以推进转化。
局限性
- 保护效果仅在小鼠脓毒症模型中验证,尚未在人体或其它动物模型确认。
- 研究聚焦单一OmpA环3表位构建体,未评估广谱菌株覆盖能力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acinetobacter baumannii has emerged as a critical nosocomial pathogen due to its extensive antimicrobial resistance and limited treatment options, highlighting the urgent need for effective vaccines. In this study, we developed and evaluated a rationally engineered epitope-based vaccine targeting extracellular loop 3 of outer membrane protein A (OmpA). Using an integrated immunoinformatics and experimental pipeline, the selected OmpA loop was grafted onto a loopless C-lobe (LCL) scaffold derived from transferrin-binding protein B to preserve native-like conformation and enhance epitope presentation. Four hybrid constructs were designed and comprehensively evaluated through computational analyses, including antigenicity prediction, structural modeling, molecular dynamics simulation, Toll-like receptor docking, and MHC-II binding assessment. Among them, OmpAL3-P2 exhibited the most favorable structural stability, surface accessibility, and epitope preservation profile. Experimental validation demonstrated successful recombinant expression and purification of the selected construct. Immunization of C57BL/6 mice with OmpAL3 induced strong antigen-specific humoral and cellular immune responses characterized by elevated IgG, predominant IgG2c production, enhanced splenocyte proliferation, and increased IFN-γ secretion, indicating a Th1-skewed response. In murine sepsis challenge models, OmpAL3 conferred significant protection, reduced bacterial burdens in major organs, and preserved tissue integrity. Passive immunization experiments further confirmed the protective contribution of vaccine-induced antibodies. Collectively, these findings demonstrate that LCL-scaffolded OmpA loop 3 is a promising subunit vaccine candidate against multidrug-resistant A. baumannii and supports the utility of scaffold-based structural vaccinology for rational vaccine development.
引用
- Banisaeed SR, Rasooli I, Ghazanfari T, et al. An integrated immunoinformatics and experimental pipeline identifies an LCL-scaffolded OmpA loop 3 construct as a protective vaccine candidate against Acinetobacter baumannii. Vaccine. 2026. PMID: 42822178. doi:10.1016/j.vaccine.2026.129205
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。